These data show that d-monobodies binding to the Abl1 SH2 domain are able to inhibit the kinase activity of Bcr-Abl, which is crucial for BCR::ABL1 signaling and CML maintenance. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.